Scinai Immunotherapeutics (SCNI) Receivables - Other (2020 - 2026)

Scinai Immunotherapeutics (SCNI) has 7 years of Receivables - Other data on file, last reported at $350.0 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other changed N/A year-over-year to $350.0 million; the trailing twelve-month figure through Mar 2026 stood at $350.0 million (changed N/A YoY), and the FY2025 full-year result was $170.0 million, up 79712.21% from the prior year.
• Receivables - Other climbed to $350.0 million in Q1 2026, from $170.0 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $350.0 million in Q1 2026 to a low of -$123000.0 in Q1 2022.
• A 5-year average of $34.8 million and a median of $228000.0 in 2023 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other slumped 52.45% in 2022 and surged 79712.21% in 2025, its largest moves.
• Tracing SCNI's Receivables - Other over 5 years: stood at $155000.0 in 2022, then jumped by 181.94% to $437000.0 in 2023, then plunged by 51.26% to $213000.0 in 2024, then surged by 79712.21% to $170.0 million in 2025, then jumped by 105.88% to $350.0 million in 2026.
• Business Quant data shows SCNI's Receivables - Other at $350.0 million in Q1 2026, $170.0 million in Q4 2025, and $236000.0 in Q2 2025.